Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the ideal therapy for melanoma in the adjuvant setting.
Considering Targeted Therapies When Managing Young Patients With mCRC
March 27th 2023In an interview with Targeted Oncology, Jennifer Y. Wo, MD, highlighted emerging discussions in the metastatic colorectal cancer space, where targeted therapies play a role, and what the next steps for research include.
Read More
Ruxolitinib Extended-Release Could Mitigate Risk/Increase Compliance for Patients With MPNs
March 24th 2023In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, provided an in-depth discussion on the complete response letter issued to ruxolitinib extended-release, and why continued evaluation of the agent could be beneficial for patients with MPNs.
Read More
2 Clarke Drive
Cranbury, NJ 08512